Shanghai Pharmaceuticals to acquire Cardinal Health’s distribution business in China for $557m

In a significant move within the pharmaceutical sector, Shanghai Pharmaceuticals Holding Co. has agreed to purchase the Chinese pharmaceutical distribution business of US-based Cardinal Health for $557 million. The deal, announced amid looming drug distribution reforms in China, marks a major shift for Cardinal Health as it reevaluates its growth strategy in the region.

Details of the Transaction

The acquisition includes Cardinal Health’s pharmaceutical and medical products distribution operations in China but excludes other segments such as Cordis, the recently acquired Patient Recovery business, the medical sourcing team, and other ongoing activities in China. The overall enterprise value of Cardinal Health China is pegged at $1.2 billion, inclusive of $643 million in shareholder loans.

Corporate Statements on the Deal

George Barrett, Chairman and CEO of Cardinal Health, expressed his views on the divestiture: “It has been an honor to serve the people of China through our distribution business for the past seven years. We recognize that significant scale is required to be a market leader in China and with that in mind, we are delighted to announce that Shanghai Pharma has agreed to purchase our distribution business in China.”

On the other side, Zhou Jun, chairman of Shanghai Pharma, highlighted the strategic importance of this acquisition: “Amid the national healthcare reform, the acquisition of the Cardinal Health China business will further strengthen our leadership in the distribution and retail pharmacy network, and expedite our transformation to become a modern global healthcare provider. This will also facilitate the growth of our pharmaceutical manufacturing business, enabling us to play a significant role in the Government’s ‘Healthy China’ initiative.”

Implications and Future Prospects

This acquisition is expected to significantly enhance Shanghai Pharma’s capabilities and reach within China’s pharmaceutical market, aligning with national healthcare goals and reforms. It promises to expand Shanghai Pharma’s influence as a distributor and retail pharmacy network, positioning the company as a key player in China’s healthcare sector.

Finalization and Future Steps

The deal is set to close by the end of Cardinal Health’s fiscal year, contingent upon fulfilling all closing conditions and receiving the necessary regulatory approvals. The agreement will see Cardinal Health China’s employees, infrastructure, and several systems and processes integrated into Shanghai Pharma, marking a new chapter for both entities in the evolving pharmaceutical landscape.